Search

Displaying results 3621 - 3630 of 4539 in total
  1. Drug

    Perhexiline

    go.drugbank.com/drugs/DB01074
    Approved

    Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.

  2. Drug

    Polidocanol

    go.drugbank.com/drugs/DB06811
    ApprovedInvestigational

    Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the ...

  3. Drug

    Cyproterone acetate

    go.drugbank.com/drugs/DB04839
    ApprovedInvestigational

    An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estroge...

  4. Drug

    Eflepedocokin alfa

    go.drugbank.com/drugs/DB16366
    Investigational

    [A225706, L27661] It is being developed by Evive Biotech (previously known as Generon BioMed Inc).[L27666]

  5. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA).

  6. Drug

    Bizalimogene ralaplasmid

    go.drugbank.com/drugs/DB16113
    Investigational

    Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related

  7. Drug

    Norclozapine

    go.drugbank.com/drugs/DB05766
    Investigational

    ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia.

  8. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  9. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines.

  10. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression.